| Literature DB >> 32807201 |
Tafese Beyene Tufa1,2,3, Andre Fuchs4,5, Torsten Feldt4,5, Desalegn Tadesse Galata6, Colin R Mackenzie7, Klaus Pfeffer7, Dieter Häussinger4,5.
Abstract
BACKGROUND: Raoultella are Gram-negative rod-shaped aerobic bacteria which grow in water and soil. They mostly cause nosocomial infections associated with surgical procedures. This case study is the first report of a Raoultella infection in Africa. Case presentation We report a case of a surgical site infection (SSI) caused by Raoultella planticola which developed after caesarean section (CS) and surgery for secondary small bowel obstruction. The patient became febrile with neutrophilia (19,157/µL) 4 days after laparotomy and started to develop clinical signs of a SSI on the 8th day after laparotomy. The patient continued to be febrile and became critically ill despite empirical treatment with ceftriaxone and vancomycin. Raoultella species with extended antimicrobial resistance (AMR) carrying the CTX-M-9 β-lactamase was isolated from the wound discharge. Considering the antimicrobial susceptibility test, ceftriaxone was replaced by ceftazidime. The patient recovered and could be discharged on day 29 after CS.Entities:
Keywords: Africa; Antimicrobial resistance; CTX-M-9 group; ESBL; Ethiopia; Extended spectrum β-lactamases; Nosocomial infection; Raoultella planticola
Mesh:
Substances:
Year: 2020 PMID: 32807201 PMCID: PMC7430002 DOI: 10.1186/s12941-020-00380-0
Source DB: PubMed Journal: Ann Clin Microbiol Antimicrob ISSN: 1476-0711 Impact factor: 3.944
Results of antimicrobial susceptibility testing of Raoultella planticola isolated strain
| Name of antimicrobial substance | Kirby–Bauer disc diffusion testa | VITEK® 2 result | ||
|---|---|---|---|---|
| Diameter (mm) | EUCAST interpretation | MIC | EUCAST interpretation | |
| Piperacillin | 0 | R | ≥ 128 | R |
| Piperacillin/tazobactam | 21 | S | 8 | S |
| Cefotaxime | 0 | R | 8 | R |
| Ceftazidime | 22 | S | ≤ 1 | S |
| Cefepime | 22 | I | ≤ 1 | S |
| Aztreonam | Not tested | 2 | I | |
| Imipenem | 26 | S | 0.5 | S |
| Meropenem | 27 | S | ≤ 0.25 | S |
| Amikacin | 20 | S | ≤ 2 | S |
| Gentamicin | 9 | R | ≥ 16 | R |
| Tobramycin | 12 | R | 8 | R |
| Moxifloxacin | Not tested | 2 | R | |
| Tigecycline | Not tested | 1 | S | |
| Ciprofloxacin | 17 | R | 1 | R |
| Fosfomycin | Not tested | ≤ 16 | S | |
| Colistin | Not tested | ≤ 0.5 | S | |
| Trimethoprim/sulfamethoxazole | Not tested | ≥ 320 | R | |
MIC minimum inhibitory concentration; R resistant, S sensitive, I intermediate
aResults of antimicrobial susceptibility testing (AST) was done by using disc diffusion method at Asella, Ethiopia whereas VITEK was performed at institute of Medical Microbiology and Hospital Hygiene, Düsseldorf, Germany. Both results were interpreted by using European Committee on Antimicrobial Susceptibility Testing (EUCAST) version: 08.01
Fig. 1Timeline of the development and course of the surgical site infection
Oligonucleotide sequences of the primer pairs for molecular resistant genes detection
| Primer | Sequence (5ʹ–3ʹ) | Amplicon size (bp) |
|---|---|---|
| blaSHV (F) | AGCCGCTTGAGCAAATTAAAC | 786 |
| blaSHV (R) | GTTGCCAGTGCTCGATCAGC | |
| blaTEM (F) | CATTTCCGTGTCGCCCTTATTC | 846 |
| blaTEM (R) | CCAATGCTTAATCAGTGAGGC | |
| blaCTX-M-1 (F) | CGTCACGCTGTTGTTAGGAA | 781 |
| blaCTX-M-1 (R) | ACGGCTTTCTGCCTTAGGTT | |
| blaCTX-M-2 (F) | CTCAGAGCATTCGCCGCTCA | 843 |
| blaCTX-M-2 (R) | CCGCCGCAGCCAGAATATCC | |
| blaCTX-M-9 (F) | GCGCATGGTGACAAAGAGAGTGCAA | 876 |
| blaCTX-M-9 (R) | GTTACAGCCCTTCGGCGATGATTC |
Possible extended spectrum β-lactamases (ESBLs) coding genes were screened by using conventional polymerase chain reaction (PCR)
F forward, R reverse, bp base pairs
Fig. 2Picture of blaCTX-M-9 ESBL positive result. blaCTX-M-9 ESBL gene detected in the isolated R. planticola strain (with M = DNA ladder; −K = negative control; + K = positive control; 285 = code given for patient’s sample